FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology firm with a market capitalization of $72.47 billion, declared a quarterly dividend and the ...

The company also announced it repurchased $750 million in BD stock to date in fiscal 2025. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in ...

The global point of care diagnostics market valued at US$ 14.26 billion in 2023, is forecasted to grow at a robust CAGR of 8.5%, reaching US$ 15.05 billion in 2024 and an impressive US$ 22.63 billion ...

The global lateral flow assay (LFA) market, valued at USD 4.3 billion in 2023, is projected to grow steadily at a CAGR of 4.7 ...

Babson Diagnostics, a science-first healthcare technology company, today announced that BetterWay™ blood testing is a ...

Company will spotlight sustainable solutions to enhance patient safety, workforce well-being, and care delivery efficiency ...

Franklin Lakes, New Jersey Saturday, January 25, 2025, 10:00 Hrs [IST] ...

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...

NYSE:BDX) BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and ...

Not-for-profit healthcare organisation Carilion Clinic is set to provide needle-free blood draws to patients leveraging Becton, Dickinson and Company’s (BD) blood collection device.